跨越界限:脊柱肌肉缩管理的未来方向
Fiona Moultrie1, Laura Chiverton1, Isabel Hatami1
1MDUK Oxford Neuromuscular Centre, Department of Paediatrics, University of Oxford, Oxford, OX3 9DU, UK; NIHR Oxford Biomedical Research Centre, Oxford, OX3 9DU, UK.
Trends in molecular medicine
|January 10, 2025
概括
脊髓肌缩 (SMA) 治疗已经改变了以前无法治疗的儿童神经肌肉疾病. 新疗法改善了患者的治疗结果,但也带来了复杂的护理挑战.
科学领域:
- 神经学 神经学
- 遗传学 是一个遗传学.
- 儿科 儿科 儿科
背景情况:
- 脊椎肌肉缩 (SMA) 是一种严重的儿科神经肌肉疾病.
- 以前,SMA是无法治疗的,导致严重的残疾和死亡率.
- 30年前的基因发现为治疗进步铺平了道路.
研究的目的:
- 审查新批准的SMA疾病修饰疗法 (DMT) 的影响.
- 讨论优化患者护理和临床结果的策略.
- 探索SMA治疗开发的未来方向.
主要方法:
- 关于SMA病理生理学和治疗的当前文献的综述.
- 对已批准的SMA疾病修饰疗法 (DMT) 的分析.
- 讨论临床管理策略和未来的研究.
主要成果:
- 目前已批准了三种DMT,这大大改变了SMA的临床过程.
- 这些疗法可减少SMA患者的残疾并延长SMA患者的生存期.
- 由于疗法变化,患者护理面临新的挑战.
结论:
- 早期诊断和治疗对于最大限度地提高SMA的结果至关重要.
- 优化剂量,结合疗法和高级物理治疗是关键.
- 开发针对替代机制的新疗法对于未来的进步至关重要.
关键词:
新生儿查 新生儿查没有任何的 nusinersenersen.在另一种类型的生物中,我们发现了一种类型的生物,它叫做Abeparvovec.物理治疗,物理治疗.里斯迪普拉姆的风险脊柱肌肉缩 脊柱肌肉缩 脊柱肌肉缩更多相关视频
07:33Conversion of Human Induced Pluripotent Stem Cells iPSCs into Functional Spinal and Cranial Motor Neurons Using PiggyBac Vectors
Published on: May 1, 2019
11.2K
10:57Intramuscular Injections Along the Motor End Plates: A Minimally Invasive Approach to Shuttle Tracers Directly into Motor Neurons
Published on: July 13, 2015
12.6K
相关概念视频
01:21Satellite Stem Cells and Muscular Dystrophy
1.9K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
1.9K
01:20Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K